Compare MSCI & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSCI | BDX |
|---|---|---|
| Founded | 1998 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6B | 48.2B |
| IPO Year | 2007 | 1998 |
| Metric | MSCI | BDX |
|---|---|---|
| Price | $560.82 | $187.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $678.53 | $194.08 |
| AVG Volume (30 Days) | 512.1K | ★ 1.7M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | 1.44% | ★ 2.22% |
| EPS Growth | ★ 11.67 | N/A |
| EPS | ★ 10.23 | 1.59 |
| Revenue | $1,274,172,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $8.75 | $2.39 |
| P/E Ratio | ★ $55.47 | $118.24 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $501.08 | $140.11 |
| 52 Week High | $644.77 | $213.08 |
| Indicator | MSCI | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 60.82 |
| Support Level | $552.51 | $175.60 |
| Resistance Level | $565.54 | $192.41 |
| Average True Range (ATR) | 9.07 | 3.91 |
| MACD | 3.00 | 0.70 |
| Stochastic Oscillator | 77.64 | 83.71 |
MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. MSCI boasts over $18 trillion (as of December 2025) in benchmarked assets, including over $2.3 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. In its sustainability and climate segment, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.